Matthew Jordan Klebanoff, MD

Doshi JA, Klebanoff MJ, Merchant M, Li P, Kazi DS PCSK9 Inhibitor Price Reductions and Medicare Part D Utilization and Spending. , JAMA Cardiol., 11(9): 2026,892-894

Doshi JA, Li P, Geng Z, Klebanoff MJ, Pettit AR, Armstrong KA, Huntington SF, Lin JK Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients. , J Clin Oncol.: 2026

Klebanoff MJ, Lin JC, Long JA, Bressman E, Doshi JA Reasons for and Outcomes of Medicare Part D Appeals for Denied GLP-1 Receptor Agonist Claims. , Diabetes Obes Metab., 28(11): 2026,10878-10881

Chesnokova A, Mumford SL, Schachter A, Hamm RF, Lorch S, Klebanoff MJ, Lindley S, Harness E, Williams M, Schapira MM Insurance Type and Menopausal Hormone Therapy Use Among US Women. , JAMA Netw Open., 9(7): 2026,e2623740

Klebanoff M, Geng Z, Li P, Tran G, Doshi J Variation in Coverage and Prior Authorization Requirements for Glucagon-like Peptide-1 Receptor Agonist Weight Loss Medications across U.S. Insurance Types. , AcademyHealth Annual Research Meeting (Podium Presentation).: 2026

Doshi JA, Li P, Geng Z, Klebanoff MJ, Pettit AR, Armstrong KA, Huntington SF, Lin JK Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients. , J Clin Oncol, American Society of Clinical Oncology Annual Meeting (Poster Presentation)., 44(16_suppl): 2026,11031

Li P, Doshi J, Klebanoff M Impact of Medicare Part D Cost Sharing on Utilization of Insulin and Novel Diabetes Medications. , Diabetes, American Diabetes Association Scientific Sessions (Poster Presentation)., 75(Suppl 1): 2026,1981-P

Klebanoff M, Geng Z, Li P, Chahin S, Doshi J Formulary Exclusions and Non-Adherence to Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D. , Value Health, ISPOR Annual International Meeting (Poster Presentation)., 29(6 Suppl): 2026

Klebanoff M, Geng Z, Li P, Tran G, Doshi J Access to Glucagon-Like Peptide-1 Receptor Agonist Antiobesity Medications: Formulary Coverage and Prior Authorization Restrictions Across U.S. Payers. , Value Health, ISPOR Annual International Meeting (Poster Presentation)., 29(6 Suppl): 2026,S221

Klebanoff MJ, Lin JC, Long JA, Doshi JA Medicare Part D Appeals of Denied Prescriptions for Glucagon-like Peptide-1 Receptor Agonists, 2020-2025. , Society of General Internal Medicine Annual Meeting (Poster Presentation).: 2026